Literature DB >> 9791038

Cytotoxic T-lymphocytes against malaria and tuberculosis: from natural immunity to vaccine design.

A Lalvani1, A V Hill.   

Abstract

1. Mycobacterium tuberculosis and the liver stage of Plasmodium falciparum are intracellular pathogens which are potentially susceptible to cytotoxic T-lymphocytes, a crucial component of the protective immune response to viral infections. Evidence from animal models points to a protective role for cytotoxic T-lymphocytes against M. tuberculosis and P. falciparum, but cytotoxic T-lymphocytes specific for these pathogens have been difficult to identify in man.2. Using a reverse immunogenetic approach, candidate epitopes from selected antigens of P. falciparum and M. tuberculosis were used to detect peptide-specific cytotoxic T-lymphocyte responses in individuals exposed to these pathogens. Cytotoxic T-lymphocyte activity was detected by the 51Cr release cytotoxicity assay and a sensitive ELISPOT assay for single-cell interferon-gamma release.3. In naturally exposed, partially immune Africans in The Gambia, eight largely conserved cytotoxic T-lymphocyte epitopes in P. falciparum, restricted by several different HLA class I alleles, were identified. Several epitopes were also recognized in Tanzanians and cytotoxic T-lymphocytes recognized endogenously processed antigen.4. In tuberculosis patients with HLA-B52, a CD8+ cytotoxic T-lymphocyte epitope was identified in ESAT-6, a secreted antigen specific for M. tuberculosis complex but absent in BCG. Cytotoxic T-lymphocytes exhibited HLA-B52-restricted peptide-specific interferon-gamma release and lytic activity and recognized endogenously processed antigen.5. These studies demonstrate that CD8+ cytotoxic T-lymphocytes specific for mycobacterial and protozoal antigens are induced during natural infections in humans. The identification of these T-cells endorses current strategies to develop cytotoxic T-lymphocyte-inducing vaccines against P. falciparum and M. tuberculosis and highlights candidate antigens for inclusion in subunit vaccines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9791038     DOI: 10.1042/cs0950531

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  8 in total

1.  Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.

Authors:  Susana A Laucella; Damián Pérez Mazliah; Graciela Bertocchi; María G Alvarez; Gretchen Cooley; Rodolfo Viotti; María C Albareda; Bruno Lococo; Miriam Postan; Alejandro Armenti; Rick L Tarleton
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

2.  An adaptation of recombinant vaccinia-based ELISPOT and intracellular cytokine staining for a comparative measurement of cellular immune responses in HIV-1 and HIV-2 infections in West Africa.

Authors:  A Eshofonie; M Shim van der Loeff; H Whittle; A Jaye
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

3.  Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides.

Authors:  Lbachir BenMohamed; Alan Thomas; Pierre Druilhe
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

Review 4.  Immunological Characterization of Proteins Expressed by Genes Located in Mycobacterium tuberculosis-Specific Genomic Regions Encoding the ESAT6-like Proteins.

Authors:  Abu Salim Mustafa
Journal:  Vaccines (Basel)       Date:  2021-01-07

Review 5.  Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data.

Authors:  Vasee S Moorthy; W Ripley Ballou
Journal:  Malar J       Date:  2009-12-30       Impact factor: 2.979

6.  HLA Class I-T cell epitopes from trans-sialidase proteins reveal functionally distinct subsets of CD8+ T cells in chronic Chagas disease.

Authors:  María G Alvarez; Miriam Postan; D Brent Weatherly; María C Albareda; John Sidney; Alessandro Sette; Carina Olivera; Alejandro H Armenti; Rick L Tarleton; Susana A Laucella
Journal:  PLoS Negl Trop Dis       Date:  2008-09-03

7.  The Significance of Discordant Serology in Chagas Disease: Enhanced T-Cell Immunity to Trypanosoma cruzi in Serodiscordant Subjects.

Authors:  Melisa D Castro Eiro; María G Alvarez; Gretchen Cooley; Rodolfo J Viotti; Graciela L Bertocchi; Bruno Lococo; María C Albareda; Ana M De Rissio; María A Natale; Cecilia Parodi; Rick L Tarleton; Susana A Laucella
Journal:  Front Immunol       Date:  2017-09-15       Impact factor: 7.561

8.  Distinct Treatment Outcomes of Antiparasitic Therapy in Trypanosoma cruzi-Infected Children Is Associated With Early Changes in Cytokines, Chemokines, and T-Cell Phenotypes.

Authors:  María C Albareda; María A Natale; Ana M De Rissio; Marisa Fernandez; Alicia Serjan; María G Alvarez; Gretchen Cooley; Huifeng Shen; Rodolfo Viotti; Jacqueline Bua; Melisa D Castro Eiro; Myriam Nuñez; Laura E Fichera; Bruno Lococo; Karenina Scollo; Rick L Tarleton; Susana A Laucella
Journal:  Front Immunol       Date:  2018-09-13       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.